These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 17699280

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Beneficial action of candesartan cilexetil plus amlodipine or ACE inhibitors in chronic nondiabetic renal disease.
    Homma K, Hayashi K, Kanda T, Yoshioka K, Takamatsu I, Tatematsu S, Kumagai H, Wakino S, Saruta T.
    J Hum Hypertens; 2004 Dec; 18(12):879-84. PubMed ID: 15295613
    [Abstract] [Full Text] [Related]

  • 3. Effects of dual blockade of the renin-angiotensin system in primary proteinuric nephropathies.
    Luño J, Barrio V, Goicoechea MA, González C, de Vinuesa SG, Gómez F, Bernis C, Espinosa M, Ahijado F, Gómez J, Escalada P.
    Kidney Int Suppl; 2002 Dec; (82):S47-52. PubMed ID: 12410855
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH, Cha SH, Lee HJ, Lee SW, Park GH, Lee SW, Kim MJ.
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [Abstract] [Full Text] [Related]

  • 6. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR.
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [Abstract] [Full Text] [Related]

  • 7. Dual blockade of the renin-angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure.
    Kincaid-Smith P, Fairley KF, Packham D.
    Nephrol Dial Transplant; 2004 Sep; 19(9):2272-4. PubMed ID: 15252156
    [Abstract] [Full Text] [Related]

  • 8. Long-term antiproteinuric effect of dual renin-angiotensin system blockade.
    Robles NR, Fernandez Carbonero E, Romero B, Sánchez Casado E, Cubero JJ.
    Cardiovasc Ther; 2009 Sep; 27(2):101-7. PubMed ID: 19426247
    [Abstract] [Full Text] [Related]

  • 9. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
    Tylicki L, Rutkowski P, Renke M, Larczyński W, Aleksandrowicz E, Lysiak-Szydlowska W, Rutkowski B.
    Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
    [Abstract] [Full Text] [Related]

  • 10. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H, Hayashi K, Saruta T.
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [Abstract] [Full Text] [Related]

  • 11. Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial.
    McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA, CHARM Investigators.
    Am Heart J; 2006 May; 151(5):985-91. PubMed ID: 16644319
    [Abstract] [Full Text] [Related]

  • 12. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
    Philipp T, Martinez F, Geiger H, Moulin B, Mourad G, Schmieder R, Lièvre M, Heemann U, Legendre C.
    Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
    [Abstract] [Full Text] [Related]

  • 15. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A, Tabata M, Hayashi K, Saruta T.
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [Abstract] [Full Text] [Related]

  • 16. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.
    Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G.
    Am J Kidney Dis; 2008 Sep; 52(3):475-85. PubMed ID: 18468748
    [Abstract] [Full Text] [Related]

  • 17. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
    Iimura O, Kusano E, Tanba K, Yanagiba S, Amemiya M, Ando Y, Honma S, Muto S, Asano Y.
    Nihon Jinzo Gakkai Shi; 2003 Jul; 45(5):439-44. PubMed ID: 14509219
    [Abstract] [Full Text] [Related]

  • 18. Functional and partial morphological regression of established renal injury in the obese zucker rat by blockade of the renin-angiotensin system.
    Sebeková K, Lill M, Boor P, Heidland A, Amann K.
    Am J Nephrol; 2009 Jul; 29(3):164-70. PubMed ID: 18753741
    [Abstract] [Full Text] [Related]

  • 19. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.
    Manno C, Torres DD, Rossini M, Pesce F, Schena FP.
    Nephrol Dial Transplant; 2009 Dec; 24(12):3694-701. PubMed ID: 19628647
    [Abstract] [Full Text] [Related]

  • 20. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.